Work

Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL

Year: 2017

Type: article

Source: Leukemia & lymphoma/Leukemia and lymphoma

DOI: 10.1080/10428194.2017.1376746

Authors: Niamh Appleby, David O’Brien, Fiona M. Quinn, Liam Smyth, Johanna Kelly, Imelda Parker, Kathleen Scott, Mary R. Cahill, Gerard Crotty, Helen Enright, Brian Hennessy, Andrew Hodgson, Maeve Leahy, Hilary O’Leary, Michael O’Dwyer, Amjad Hayat, Elisabeth A. Vandenberghe

Institutions: Trinity College Dublin, St. James's Hospital, Children's Health Ireland at Crumlin, Cancer Trials Ireland, Cork University Hospital, Midland Regional Hospital at Tullamore, Tallaght University Hospital, University Hospital Waterford, Sligo University Hospital, University Hospital Limerick, University Hospital Galway

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Health Research Board

Award: G9000370754

OpenAlex ID: W2755812911

FWCI: 0.826

Cites: 53

Cited by: 7

Related to: 10